Journal
IMMUNITY
Volume 52, Issue 5, Pages 856-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2020.03.001
Keywords
-
Categories
Funding
- MINECO [SAF2017-83267-C2-1-R]
- immuno-oncology network of Bristol-Myers Squibb (I-ON)
- European Union [635122 -PROCROP]
- Fundacion de la Asociacion Espanola Contra el Cancer (AECC)
- la Caixa'' Banking Foundation [LCF/BQ/LR18/11640014]
Ask authors/readers for more resources
Neutrophils are expanded and abundant in cancer-bearing hosts. Under the influence of CXCR1 and CXCR2 chemokine receptor agonists and other chemotactic factors produced by tumors, neutrophils, and granulocytic myeloid-derived suppressor cells (MDSCs) from cancer patients extrude their neutrophil extracellular traps (NETs). In our hands, CXCR1 and CXCR2 agonists proved to be the major mediators of cancer-promoted NETosis. NETs wrap and coat tumor cells and shield them from cytotoxicity, as mediated by CD8(+) T cells and natural killer (NK) cells, by obstructing contact between immune cells and the surrounding target cells. Tumor cells protected from cytotoxicity by NETs underlie successful cancer metastases in mice and the immunotherapeutic synergy of protein arginine deiminase 4 (PAD4) inhibitors, which curtail NETosis with immune checkpoint inhibitors. Intravital microscopy provides evidence of neutrophil NETs interfering cytolytic cytotoxic T lymphocytes (CTLs) and NK cell contacts with tumor cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available